Insider · CIK 0001825322
Reshma Rangwala
Files at KPTI (Karyopharm Therapeutics Inc.). First filing Mar 6, 2025, latest Mar 3, 2026.
Reshma Rangwala files SEC Form 4 as officer at KPTI (Karyopharm Therapeutics Inc.). Since Mar 6, 2025, Reshma Rangwala has reported 0 open-market buys worth $0 and 4 open-market sells worth $75k, the latest filed on Mar 3, 2026.
A track record needs three past buys with six months of prices behind them; Reshma Rangwala has 0, so none is measured yet.
The newest scored trade: sold $48k of KPTI on Mar 2, 2026, filed Mar 3, 2026, scored 37 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $48k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KPTI: Karyopharm Therapeutics Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Karyopharm Therapeutics Inc. | $48k 5,066 shares | -8% | +171% from low-5% from high | |
| 30Weak | Karyopharm Therapeutics Inc. | $2,623 408 shares | -1% | +77% from low-58% from high | |
| 23Weak | Karyopharm Therapeutics Inc. | $2,585 419 shares | -1% | +77% from low-58% from high | |
| 35Weak | Karyopharm Therapeutics Inc. | $23k 3,587 shares | -11% | - |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -5,066 | $9.41 | $48k | 56,739 | Mar 3, 2026 |
| Jan 31, 2026 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Common Stock | +32,415 | $0.00 | $0 | 61,805 | Feb 3, 2026 |
| Sep 12, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Common Stock | +945 | $0.00 | $0 | 29,798 | Sep 16, 2025 |
| Sep 15, 2025 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -408 | $6.43 | $2,623 | 29,390 | Sep 16, 2025 |
| Apr 23, 2025 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -419 | $6.17 | $2,585 | 28,853 | Apr 24, 2025 |
| Mar 4, 2025 | KPTI Karyopharm Therapeutics Inc. | SOpen-market sale Common Stock | -3,587 | $6.29 | $23k | 29,272 | Mar 6, 2025 |
| Feb 28, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Common Stock | +5,416 | $0.00 | $0 | 28,276 | Mar 4, 2025 |
| Feb 28, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Common Stock | +4,583 | $0.00 | $0 | 32,859 | Mar 4, 2025 |
| Feb 28, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +10,833 | $0.00 | $0 | 10,833 | Mar 4, 2025 |
| Feb 28, 2025 | KPTI Karyopharm Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +9,166 | $0.00 | $0 | 9,166 | Mar 4, 2025 |
Questions about Reshma Rangwala
Answered from the filings on this page, as of the latest one.
Is Reshma Rangwala buying or selling?
In the last 12 months Reshma Rangwala reported 0 open-market buys worth $0 and 1 open-market sell worth $48k on SEC Form 4; the latest was sold $48k of KPTI on Mar 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Reshma Rangwala's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Reshma Rangwala has 0.
Where does Reshma Rangwala file Form 4?
Reshma Rangwala has filed Form 4 at KPTI (Karyopharm Therapeutics Inc.) as EVP & Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.